MoonLake Immunotherapeutics (MLTX) Assets Average (2021 - 2026)

MoonLake Immunotherapeutics' Assets Average history runs 6 years deep, the most recent figure standing at $412.4 million for Q1 2026.

• In Q1 2026, Assets Average fell 16.62% year-over-year to $412.4 million; the TTM figure through Mar 2026 stood at $412.4 million (down 16.62% YoY), while the FY2025 annual figure was $451.2 million, down 10.17% from the prior year.
• Assets Average was $412.4 million for Q1 2026 at MoonLake Immunotherapeutics, down from $419.4 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $554.5 million in Q2 2024 to a low of $71.8 million in Q1 2023.
• Historically, Assets Average has averaged $365.6 million across 5 years, with a median of $437.2 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Assets Average sank 40.37% in 2023, then jumped 659.3% in 2024.
• A 5-year view of Assets Average shows it stood at $82.7 million in 2022, then soared by 520.64% to $513.4 million in 2023, then dropped by 2.98% to $498.1 million in 2024, then dropped by 15.8% to $419.4 million in 2025, then declined by 1.66% to $412.4 million in 2026.
• The last three Assets Average figures came in at $412.4 million (Q1 2026), $419.4 million (Q4 2025), and $437.2 million (Q3 2025), per Business Quant data.